Advancing Hope: AFTD Attends the Tau Global Conference
In late April, AFTD Research team members attended a premier conference focused exclusively on research into tau, a protein which is aggregated in Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), MAPT Frontotemporal Degeneration, Alzheimer’s Disease, and other neurodegenerative disorders. This conference was co-hosted by the Alzheimer’s Association, CurePSP, and the Rainwater Charitable Foundation. It brought…
Read MoreBrain Pathology Consistent with FTD Found in Roughly 35% of Motor Neuron Disease Cases in Recent Study
According to a recent study published in the research journal Brain, brain pathology consistent with FTD was detected in roughly 35% of the participants with motor neuron disease, which includes diseases like ALS. Abnormal protein clumps were detected in 90% of the samples studied, with participants classified as having both FTD and motor neuron disease…
Read MorePromising FTD Gene Therapy from AviadoBio Featured in the UK Guardian
In London’s Docklands, British biotech company AviadoBio is developing a promising gene therapy to treat FTD. The Guardian wrote about the company’s progress on June 13. AviadoBio’s lead therapy, AVB-101, targets the specific genetic form FTD-GRN, caused by mutations that create a deficiency in progranulin, a protein essential for healthy brain cells. The treatment represents…
Read MoreFTD Science Digest: Help Advance Science by Joining the Updated FTD Disorders Registry
It is a pivotal time for FTD clinical research. New therapies have advanced to phase 3 clinical trials. Treatments for FTD caused by variants in specific genes are closer than ever. Trials targeting sporadic FTD are also emerging, such as an ongoing trial on semantic variant primary progressive aphasia (svPPA) and an upcoming platform trial…
Read MoreFTD Research Spotlight: A New Researcher Portal and Other Updates from the FTD Disorders Registry
It is a pivotal time for FTD clinical research. New therapies have advanced to phase 3 clinical trials. Treatments for FTD caused by variants in specific genes are closer than ever. Trials targeting sporadic FTD are also emerging, such as an ongoing trial on semantic variant primary progressive aphasia (svPPA) and an upcoming platform trial…
Read MoreAFTD Webinar: Speech Language Therapy — A Promising Practice in FTD Treatment and Care
When patients lose the ability to communicate effectively, doctors and other clinicians often refer them to a speech language pathologist (SLP) to help them regain their speaking skills. But for patients with the FTD disorder known as primary progressive aphasia (PPA), lost speaking abilities do not return, and communication only gets worse as the brain…
Read More
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)